Regarding to the fact that all papillary thyroid carcinomas with metastasis have shown to bear TSHr methylation in our study, patients with metastatic disease may become the first candidates for such a potential therapy with de-methylating agents in the future. This evidence concerns the gene TSHR and thyroid gland papillary carcinoma.